G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation

Bortezomib is a proteasome inhibitor approved for anticancer therapy. However, variable sensitivity of tumor cells exists in this therapy probably due to differences in the expression of proteasome subunits. G(alpha)(12/13) serves modulators or signal transducers in diverse pathways. This study inve...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Carcinogenesis (New York) 2010-07, Vol.31 (7), p.1230-1237
Hauptverfasser:	Yang, Yoon Mee, Lee, Sanghwan, Nam, Chang Won, Ha, Ji Hee, Jayaraman, Muralidharan, Dhanasekaran, Danny N, Lee, Chang Ho, Kwak, Mi-Kyoung, Kim, Sang Geon
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Boronic Acids - pharmacology Bortezomib Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Cell Line GTP-Binding Protein alpha Subunits, G12-G13 - antagonists & inhibitors GTP-Binding Protein alpha Subunits, G12-G13 - physiology Humans In Situ Nick-End Labeling Liver Neoplasms - drug therapy Liver Neoplasms - pathology Protease Inhibitors - pharmacology Proteasome Endopeptidase Complex - genetics Proteasome Inhibitors Pyrazines - pharmacology RNA, Messenger - analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!